LXRX Q3 2019 Earnings — Lexicon Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

LXRXLexicon Pharmaceuticals, Inc.

$693M

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$294M+4194.7% YoY

Gross Profit

$294M99.8% margin

Operating Income

$225M76.3% margin

Net Income

$226M76.8% margin

EPS (Diluted)

$1.95

QoQ Revenue Growth

+2941.2%

Cash Flow

Operating Cash Flow

$191M

Free Cash Flow

$191M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$445M

Total Liabilities

$280M

Stockholders' Equity

$165M

Cash & Equivalents

$170M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$294M	$7M	+4194.7%
Gross Profit	$294M	$6M	+4560.9%
Operating Income	$225M	-$23M	+1075.0%
Net Income	$226M	-$28M	+921.8%